Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

Group 1 - The overall industry sentiment shows an upward trend in sectors such as steel, electric equipment, electronics, food and beverage, environmental protection, and retail, while sectors like oil and petrochemicals, machinery, light manufacturing, home appliances, automotive, banking, real estate, and public utilities are experiencing a downward trend [3][22] - As of August 10, 2025, notable industry data includes: automotive semi-steel tire operating rate at 74.35%, down 0.1% month-on-month; machinery equipment price index at 125.17 points, down 0.11% month-on-month; electric equipment Topcon component price at 0.7 yuan/watt, up 4.2% month-on-month; transportation with Suzhou subway passenger volume at 2.156 million, up 27.57% month-on-month; light manufacturing white cardboard price at 4010 yuan/ton, down 2.43% month-on-month [3][23][24] Group 2 - Insurance capital is increasingly allocating to equity, with banks and high-dividend sectors being core beneficiaries. By the end of Q1 2025, life and property insurance companies had invested a total of 2.82 trillion yuan in the stock market, a year-on-year increase of 44.5% [5] - The potential for insurance capital to increase its allocation to bank stocks remains significant, with estimated incremental funds of 140.4 billion yuan and 73.7 billion yuan for bank stocks in 2025, assuming 25% of new premium income is directed to the A-share market [5] Group 3 - The report on Shiyao Group indicates a revenue of 7.015 billion yuan in Q1 2025, a year-on-year decrease of 21.9%, with a net profit of 1.495 billion yuan, down 8.3%. The decrease in revenue is primarily due to the impact of price adjustments and centralized procurement policies [8][28] - The core pipeline SYS6010 (EGFRADC) shows strong potential for authorization, having started its first phase III clinical trial in March 2025, targeting patients with EGFR mutation non-small cell lung cancer [8][28] Group 4 - Shenzhen Airport's operational data shows a significant recovery, with 221,000 aircraft movements in the first half of 2025, a year-on-year increase of 7.2%, and a passenger throughput of 32.57 million, up 10.9% year-on-year [19][30] - The airport's non-aeronautical business is diversifying, with advertising revenue expected to increase as passenger traffic grows, and the new cargo station is anticipated to boost international cargo volume [19][31] Group 5 - Beiding Co. reported a revenue of 430 million yuan in the first half of 2025, a year-on-year increase of 34%, with a net profit of 56 million yuan, up 75% year-on-year. The company benefited significantly from domestic subsidies and the "old-for-new" replacement policy [10][36] - The company's gross margin improved to 49.7% in the first half of 2025, driven by high-margin products, with a notable increase in sales from new product lines [10][36]

Group 1 - Xiaomi Group-W (01810), SMIC (00981), and Alibaba-W (09988) ranked the top three in net inflow of southbound funds, with net inflows of 1.716 billion, 0.497 billion, and 0.492 billion respectively [1] - The top three stocks with the highest net outflow of southbound funds were the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and China Mobile (00941), with net outflows of -4.725 billion, -1.560 billion, and -0.794 billion respectively [1] - In terms of net inflow ratio, Reshape Energy (02570), Haitian International (01882), and Guofu Hydrogen Energy (02582) led the market with ratios of 69.81%, 56.10%, and 54.91% respectively [1] Group 2 - The top ten stocks by net inflow included Xiaomi Group-W (01810) with 1.716 billion and a closing price of 51.850, down 3.98% [2] - The top ten stocks by net outflow included the Tracker Fund of Hong Kong (02800) with -4.725 billion and a closing price of 25.560, up 0.55% [2] - The highest net inflow ratio was recorded by Reshape Energy (02570) at 69.81% with a closing price of 167.000, up 1.33% [3]

Core Viewpoint - The company is expected to see performance growth driven by authorized income and new product varieties, showcasing its R&D capabilities through eight major platforms [1]. Group 1: Financial Performance - In Q1 2025, the company reported revenue of 7.015 billion yuan, a year-on-year decrease of 21.9%, and a net profit attributable to shareholders of 1.495 billion yuan, down 8.3% year-on-year [1]. - The revenue from the traditional medicine business decreased by 27.3% year-on-year, but new authorized income reached 718 million yuan, significantly alleviating the pressure from centralized procurement and medical insurance policies [1]. Group 2: R&D and Product Pipeline - The company has ten ADC pipelines in clinical stages, with key products SYS6010 (EGFR ADC) showing strong potential for authorization [1]. - SYS6010 started its first Phase III clinical trial in March 2025, targeting EGFR mutation-positive locally advanced or metastatic NSCLC patients who have failed EGFR-TKI treatment [1]. - SYS6010 has received three FDA Fast Track Designations (FTD) for various indications, including metastatic non-small cell lung cancer [1]. Group 3: Expansion into Chronic Disease Management - The company is expanding into chronic disease management, focusing on cardiovascular and endocrine metabolic fields [2]. - The GLP-1 series products, including the new drug TG103, are expected to benefit patients with diabetes and obesity, with clinical trials for both conditions expected to lead to market applications in 2025 and 2026 [2]. - Small RNA drugs such as PCSK9 siRNA, AGT siRNA, and Lp(a) siRNA have entered clinical stages, with early data showing potential in cholesterol reduction and hypertension treatment [2]. Group 4: Profit Forecast and Valuation - The company is positioned as a leading domestic innovative pharmaceutical enterprise, with its eight innovation platforms expected to yield significant value [2]. - Projected revenues for 2025-2027 are 29.794 billion yuan, 30.455 billion yuan, and 31.585 billion yuan, with net profits of 5.575 billion yuan, 5.930 billion yuan, and 6.198 billion yuan respectively [2]. - Based on a 35x PE ratio, the estimated valuation is 195.1 billion yuan, with a target price of 16.94 yuan, equivalent to 18.63 HKD, initiating coverage with a "buy" rating [2].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 18.63 HKD, based on a current price of 10.36 HKD [6]. Core Insights - The company is positioned as a leading innovative pharmaceutical enterprise in China, with a strong focus on research and development, and a robust commercialization capability [14][19]. - The recent performance has been impacted by price adjustments and centralized procurement policies, but new licensing revenues and additional product launches are expected to drive growth [19][20]. - The company has established eight major technology platforms, showcasing its research capabilities and potential for future growth through international licensing agreements [4][29]. Summary by Sections Company Overview - The company integrates research, production, and sales, focusing on innovative drugs as its core strategy, supported by a large international R&D team and a comprehensive marketing network [14][15]. Financial Performance - In Q1 2025, the company reported revenues of 70.15 billion CNY, a year-on-year decline of 21.9%, with a net profit of 14.95 billion CNY, down 8.3% [20][22]. - The traditional pharmaceutical business, which contributes approximately 80% of total sales, has faced pressure due to centralized procurement and price adjustments [19][22]. Product Pipeline and Innovation - The company has a diverse pipeline with over 200 innovative drugs and formulations, including 10 ADC products in clinical stages, highlighting its strong R&D capabilities [33][39]. - Key products like SYS6010 (EGFR ADC) have entered critical clinical phases, with significant potential for licensing and market impact [2][45]. Market Expansion and Licensing - The company has successfully executed multiple international licensing agreements, enhancing its global presence and generating substantial licensing revenue [35][36]. - Recent collaborations with major pharmaceutical companies, such as AstraZeneca, indicate a growing recognition of the company's innovative capabilities [37][38].

Summary of Key Points Core Viewpoint - On August 11, southbound funds recorded a transaction volume of 115.814 billion HKD, with a net inflow of approximately 0.038 billion HKD, indicating mixed investor sentiment in the Hong Kong market [1]. Group 1: Major Net Buy and Sell Activities - Significant net buying was observed in Xiaomi Group-W (01810.HK) with 5.62 billion HKD, Kangfang Biotech (09926.HK) with 3.06 billion HKD, and Dongfang Zhenxuan (01797.HK) with 1.88 billion HKD [1]. - Major net selling was noted in XPeng Inc. (09868.HK) with 66.496 billion HKD, Innovent Biologics (01801.HK) with 52.789 billion HKD, and Tencent Holdings (00700.HK) with 33.983 billion HKD [1]. Group 2: Individual Stock Performance - Xiaomi Group-W experienced a decline of 0.88% with net buying of 3.70 billion HKD from the Shanghai-Hong Kong Stock Connect and 1.92 billion HKD from the Shenzhen-Hong Kong Stock Connect [1]. - Kangfang Biotech saw a slight increase of 0.25% with a net inflow of 3.06 billion HKD from the Shenzhen-Hong Kong Stock Connect [1]. - Dongfang Zhenxuan rose by 3.32%, with net buying of 2.01 billion HKD from the Shanghai-Hong Kong Stock Connect and a net sell of 131.974 million HKD from the Shenzhen-Hong Kong Stock Connect [1]. - Crystal Tech Holdings (02228.HK) increased by 4.78% with net buying of 1.17 billion HKD from the Shanghai-Hong Kong Stock Connect [2]. - CSPC Pharmaceutical Group (01093.HK) rose by 0.97% with a net inflow of 386.093 million HKD from the Shenzhen-Hong Kong Stock Connect [3]. - Hua Hong Semiconductor (01347.HK) fell by 3.68% with net buying of 360.177 million HKD from the Shanghai-Hong Kong Stock Connect [4]. - XPeng Inc. increased by 5.36% but faced significant net selling of 39.574 billion HKD from the Shanghai-Hong Kong Stock Connect and 26.922 billion HKD from the Shenzhen-Hong Kong Stock Connect [5]. - Innovent Biologics declined by 1.42% with net selling of 30.133 billion HKD from the Shanghai-Hong Kong Stock Connect and 22.656 billion HKD from the Shenzhen-Hong Kong Stock Connect [6]. - Tencent Holdings remained stable with no change in price, but had net buying of 925.043 million HKD from the Shanghai-Hong Kong Stock Connect and net selling of 43.233 billion HKD from the Shenzhen-Hong Kong Stock Connect [6]. - Meituan-W (03690.HK) decreased by 1.32% with net selling of 37.107 billion HKD from the Shanghai-Hong Kong Stock Connect and net buying of 1.06 billion HKD from the Shenzhen-Hong Kong Stock Connect [6].

Group 1 - On August 8, several stocks including Hutchison Whampoa, Nanjing Panda Electronics, Oriental Selection, Fubo Group, Zai Ding Pharmaceutical, and Huitongda Network made their debut on the Hong Kong Stock Connect active trading list for the first time in a month [1][2] - The total trading volume of active stocks on August 8 reached 33.757 billion HKD, accounting for 27.32% of the total trading amount on that day, with a net buying amount of 1.614 billion HKD [1] - Among the active stocks, SMIC had the highest trading volume at 11.074 billion HKD, followed by Alibaba and Xiaomi with trading amounts of 3.887 billion HKD and 3.800 billion HKD respectively [1] Group 2 - Hutchison Whampoa had a trading volume of 0.958 billion HKD with a net selling of 0.158 billion HKD, closing down 15.99% [2] - Nanjing Panda Electronics recorded a trading volume of 1.075 billion HKD with a net selling of 0.025 billion HKD, closing down 10.40% [2] - Oriental Selection had a trading volume of 1.024 billion HKD with a net buying of 0.056 billion HKD, closing up 12.32% [2] - Fubo Group had a trading volume of 0.747 billion HKD with a net buying of 0.031 billion HKD, closing up 18.36% [2] - Zai Ding Pharmaceutical had a trading volume of 0.768 billion HKD with a net buying of 0.217 billion HKD, closing down 10.47% [2] - Huitongda Network had a trading volume of 1.758 billion HKD with a net buying of 0.076 billion HKD, closing up 26.90% [2]

Core Insights - On August 8, 2025, SMIC (00981), Alibaba-W (09988), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 6.668 billion, 2.541 billion, and 2.286 billion respectively [1] - In the Southbound Stock Connect for Shenzhen, SMIC (00981), Xiaomi Group-W (01810), and Alibaba-W (09988) also ranked as the top three, with trading amounts of 4.406 billion, 1.514 billion, and 1.346 billion respectively [1] Southbound Stock Connect (Shanghai) - Top active companies by trading volume: - SMIC (00981): 6.668 billion with a net buy of 0.213 billion - Alibaba-W (09988): 2.541 billion with a net buy of 0.398 billion - Xiaomi Group-W (01810): 2.286 billion with a net buy of 0.547 billion - Tencent Holdings (00700): 1.916 billion with a net buy of 0.424 billion - Huizhou Network (09878): 1.758 billion with a net buy of 0.0758 billion - Hua Hong Semiconductor (01347): 1.125 billion with a net sell of 0.336 billion - Nanjing Panda Electronics (00553): 1.075 billion with a net sell of 0.0252 billion - CSPC Pharmaceutical Group (01093): 1.075 billion with a net sell of 0.133 billion - Dongfang Zhenxuan (01797): 1.024 billion with a net buy of 0.0556 billion - Jing Tai Holdings (02228): 0.956 billion with a net buy of 0.0446 billion [1] Southbound Stock Connect (Shenzhen) - Top active companies by trading volume: - SMIC (00981): 4.406 billion with a net sell of 0.639 billion - Xiaomi Group-W (01810): 1.514 billion with a net sell of 0.0745 billion - Alibaba-W (09988): 1.346 billion with a net buy of 0.333 billion - Tencent Holdings (00700): 1.214 billion with a net sell of 0.319 billion - Hutchison China MediTech (00013): 0.958 billion with a net sell of 0.158 billion - CanSino Biologics (09926): 0.893 billion with a net buy of 0.0202 billion - Zai Lab (09688): 0.768 billion with a net buy of 0.0217 billion - Innovent Biologics (01801): 0.759 billion with a net buy of 0.0745 billion - Fufeng Group (03738): 0.747 billion with a net buy of 0.0315 billion - Tracker Fund of Hong Kong (02800): 0.729 billion with a net buy of 0.0684 billion [1]

在週三（6日）的專欄【中銀做客】中，我們邀請到中銀國際董事Niki:在早前也有和Simon提到半年回顧和展望中，其中有提到醫藥股這個板 塊。總結1-6月的數據，發現醫藥股的股價跑贏大市，行業升幅60%至1倍不等。在放假的這2周的時間裏，有些個股創今年高位。市場消息上， 有了AI的幫助，整體研發的週期縮短加上創新藥在上半年的出口金額達到去年全年的金額。回到石藥，認購證可以參考中銀認購證18524，行使 價13.4元，槓桿4倍，明年2月份到期。Simon:剛才Niki分享很多醫藥股情況，如果大家想問其他個股也歡迎留言給我們，或中銀網站首頁也有不 同產品提供。回到石藥的技術分析，買賣信號為"買入"，上方的阻力位在10.54元和11.46元。 觀察石藥集團相關衍生品近期表現，8月4日至8月6日期間呈現典型的槓桿放大效應。在這兩個交易日內，雖然正股累計漲幅為4.14%，但相關認購證的表現 遠超這一幅度。摩利認購證17483在此期間累計上漲16%，中銀認購證17351也有13%的漲幅，充分展現了醫藥股窩輪產品在趨勢行情中的延時放大特性。 | 12:36 | | | 1 2 1 1 | 12:36 | | --- | -- ...

8月8日港股市场，北水成交净买入62.71亿港元，其中港股通(沪)成交净买入32.8亿港元，港股通(深)成 交净买入29.92亿港元。 北水净买入最多的个股是阿里巴巴-W(09988)、盈富基金(02800)、小米集团-W(01810)。北水净卖出最 多的个股是中芯国际(00981)、华虹半导体(01347)、和黄医药(00013)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 中芯国际 | 34.40 乙 | 32.28 乙 | 66.68 亿 | | HK 00981 | | | +2.13 乙 | | 阿里巴巴-W | 14.6917 | 10.72亿 | 25.41 乙 | | HK 09988 | | | +3.98 亿 | | 小米集团-W | 14.16亿 | 8.69亿 | 22.86亿 | | HK 01810 | | | +5.47 乙 | | 腾讯控股 | 11.70 乙 | 7.461Z | 19.16亿 | | HK 00700 | | | +4.24 乙 | | 汇通达网络 | 9.17 ...